FHM IV LLC 4
4 · Trubion Pharmaceuticals, Inc · Filed Oct 29, 2010
Insider Transaction Report
Form 4
FHM III, LLC
10% Owner
Transactions
- Disposition to Issuer
Common Stock
2010-10-28−8,291→ 0 total(indirect: Frazier Affiliates IV, L.P.) - Disposition to Issuer
Common Stock
2010-10-28−1,632,687→ 0 total(indirect: Frazier Healthcare IV, L.P.) - Disposition to Issuer
Common Stock
2010-10-28−4,457→ 0 total(indirect: Frazier Affiliates III, L.P.) - Disposition to Issuer
Common Stock
2010-10-28−592,505→ 0 total(indirect: Frazier Healthcare III, L.P.)
Footnotes (6)
- [F1]Disposed of pursuant to merger agreement among the issuer and Emergent BioSolutions Inc., and certain of its affiliates, in exchange for (a) an aggregate of $6,085.17 cash, (b) 731 shares of Emergent common stock having a market value of $18.26 per share on the effective date of the merger and (c) 4,457 contingent value rights, which represent the right to receive possible additional cash payments.
- [F2]These securities are owned directly by the entity listed. Frazier Affiliates III, L.P. and Frazier Healthcare III, L.P., are joint filers. The designated filer, FHM III, LLC, serves as the general partner of Frazier Affiliates III, L.P. and Frazier Healthcare III, L.P. FHM III, LLC disclaims beneficial ownership of the reported securities, except to the extent of its proportionate pecuniary interest therein.
- [F3]Disposed of pursuant to merger agreement among the issuer and Emergent BioSolutions Inc., and certain of its affiliates, in exchange for (a) an aggregate of $11,317.22 cash, (b) 1,360 shares of Emergent common stock having a market value of $18.26 per share on the effective date of the merger and (c) 8,291 contingent value rights, which represent the right to receive possible additional cash payments.
- [F4]These securities are owned directly by the entity listed Frazier Affiliates IV, L.P. and Frazier Healthcare IV, L.P., are joint filers. FHM IV, L.P. also a joint filer, serves as the general partner of Frazier Affiliates IV, L.P. and Frazier Healthcare IV, L.P. disclaims beneficial ownership of the reported securities, except to the extent of its proportionate pecuniary interest therein.
- [F5]Disposed of pursuant to merger agreement among the issuer and Emergent BioSolutions Inc., and certain of its affiliates, in exchange for (a) an aggregate of $808,767.96 cash, (b) 97,229 shares of Emergent common stock having a market value of $18.26 per share on the effective date of the merger and (c) 592,505 contingent value rights, which represent the right to receive possible additional cash payments.
- [F6]Disposed of pursuant to merger agreement among the issuer and Emergent BioSolutions Inc., and certain of its affiliates, in exchange for (a) an aggregate of $2,228,617.76 cash, (b) 267,923 shares of Emergent common stock having a market value of $18.26 per share on the effective date of the merger and (c) 1,632,687 contingent value rights, which represent the right to receive possible additional cash payments.